DeCure's autonomous Rare AI scientist is researching a drug-repurposing hypothesis for Antisynthetase syndrome — screening already-approved drugs against its 2-gene Open Targets disease module to publish open-access research. Research is fast; the path to publication is funded in milestone stages.
Disease moduleAntisynthetase syndrome maps to a 2-gene Open Targets module — the target space DeCure's AI scientist screens approved drugs against.
DeCure.ai methodSignature reversal (LINCS) plus network proximity (STRING) rank already-approved drugs likely to perturb this module — the same engine that produces DeCure.ai's repurposing hypotheses.
Repurposing thesisScreening approved medicines against this disease module, then publishing the evidence for the strongest candidate. Known pharmacology and human exposure data make the first question sharper — they do not establish safety or efficacy in a new indication.
Research record
01
ResearchComing soon
Candidate research + dossier — target rationale, drug-repurposing thesis and evidence pack.proof: Published dossier + on-chain hash
02
ValidationComing soon
In-vitro biological validation at a contract research org (CRO).proof: CRO contract + in-vitro report
03
Peer review & paperComing soon
Peer-reviewed paper published open-access (preprint + journal).proof: DOI + open-access link + on-chain hash
Current lead
No approved-drug candidate for antisynthetase syndrome is corroborated in the literature DeepSearch retrieved. Some conditions are managed with non-pharmacological care — a device, surgery or physical therapy — rather than a medicine; that may be the case here, or the literature we found may simply be too sparse yet to support a drug-repurposing angle.
Molecular view
interleukin 1 beta (IL1B) — IL1B is one of the genes genetically linked to this disease in Open Targets — shown as context, not as a drug target we're pursuing: no approved-drug candidate for this disease is yet corroborated in the literature we found.
Loading structure…
helix sheet 2sdrag to rotate · scroll to zoom
RCSB Protein Data Bank · entry 5R8Q · 1.23 Å · ligand 1-methyl-N-{[(2S)-oxolan-2-yl]methyl}-1H-pyrazole-3-carboxamide (JGY). Experimental structure, not a prediction.
What the evidence adds up to
A 2012 case report describes the successful use of repeated rituximab in one patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. The authors note that previous experience with rituximab in this condition had been sparse. No other patients, response rates, or survival data are reported in that paper.
A 2009 review characterises antisynthetase syndrome as a systemic, inflammatory, autoimmune disease defined by myositis, polyarthritis, and interstitial lung disease, together with autoantibodies to tRNA synthetases. It discusses the role of these antibodies in pathogenesis and current management approaches, but provides no new trial data or quantitative outcomes.
A 2022 review emphasises that antisynthetase syndrome is a rare subtype of idiopathic inflammatory myopathies, with symptoms that frequently appear asynchronously. It states that diagnosis remains a considerable challenge and is often delayed. No treatment efficacy data are presented.
What is still missing: prospective controlled trials with adequate sample sizes, validated diagnostic criteria that reduce delay, and any randomised evidence for rituximab or other targeted therapies. Patient stratification by antibody subtype or organ involvement has not been tested in a formal trial.
Evidence
Retrieved by DeepSearch across 234,678,978 indexed works and resolved on OpenAlex — ranked by citations, including the results that did not work.
Internal Medicine Journal · 2012 · 26 citations
Efficacy of rituximab in refractory antisynthetase syndrome
AbstractWe report the successful use of repeated administration of rituximab in a patient with antisynthetase syndrome refractory to conventional immunosuppressive medications. A literature review revealed that previous experience with rituximab in this condition has been sparse. The rationale for the use of B-cell depleting therapies in antisynthetase syndrome has been explored in light of the current understanding of the pathogenesis of this condition.
AbstractAntisynthetase syndrome is a systemic, inflammatory, autoimmune disease characterized by myositis, polyarthritis, and interstitial lung disease and is associated with presence of autoantibodies to transfer RNA (tRNA) synthetases (antisynthetase antibodies). We review the current literature on the role of antisynthetase antibodies in the pathogenesis of this syndrome, mechanism of injury, clinical picture of the antisynthetase syndrome, and current approach to the management of the disease.
Rheumatology Forum · 2022 · 0 citations · open access
Difficulties in the diagnosis of antisynthetase syndrome
AbstractAntisynthetase syndrome is a rare subtype of idiopathic inflammatory myopathies, characterised by co-ocurrence of myositis, arthritis, interstitial lung disease, Raynaud phenomenon, fever and mechanic’s hands. Symptoms frequently appear asynchronously. The presence of antisynthetase antibodies in a patient’s serum is considered an immunological hallmark of the disease. Arriving at a proper diagnosis of antisynthetase syndrome remains a considerable challenge, and the diagnosis is often delayed. The manuscript discusses possible obstacles in the diagnostic process of antisynthetase syndrome.
Disease module: DeepOracle (Open Targets). Structures: RDKit from PubChem SMILES. Literature: retrieved by DeepSearch across 234,678,978 indexed works (targeted per-candidate search), resolved on OpenAlex.
DeCure is a research and publication project, not medical advice and not a treatment. "DeCure for X" describes a research goal, not a claim that a cure exists. Backing a cure is a contribution to fund the research — it is not an investment, and confers no yield, royalty, equity or IP ownership. Papers are published open-access by the DeCure.ai DAO.
